Daniel O’Connell joined Novo Ventures in 2022 as Partner based in the San Francisco office.
Prior to joining Novo Ventures, Daniel was Executive Director, Equity and Venture Capital/Corporate Development at BMS, where he was responsible for managing direct equity investments and LP positions in venture funds as well as leading the evaluation and acquisition of public companies across all areas of interest to BMS. Before BMS, Daniel was an Investment Director with Arix Bioscience and a Senior Associate with Orbimed. Daniel was also Associate Director, Cardiovascular Research at Arisaph Pharmaceuticals.
Daniel completed his undergraduate degree in Chemistry and Mathematics at MIT, and his MD and PhD from Tufts University.